Curis

Historical price data

Curis, Inc. is a U.S.-based, publicly traded oncology biotech with a mission to slow, prevent, or cure cancer by prolonging life. Its primary achievement is a strategic collaboration with Roche/Genentech, which commercializes Erivedge™ for advanced basal cell carcinoma, providing a critical royalty revenue stream. The company's strategy leverages a lean, virtual model to advance a pipeline of internally discovered and in-licensed small molecule candidates, with a current focus on IRAK4 inhibition for hematologic cancers and dual HDAC/PI3K inhibition.

A hybrid strategy focused on developing small molecule inhibitors targeting key cancer biology nodes (e.g., IRAK4, dual HDAC/PI3K, oral immune checkpoints), leveraging both internal discovery and strategic in-licensing.

Faces competition in IRAK4 space from other early-stage inhibitors and degraders; in DLBCL from targeted therapies and CAR-T; and in oral checkpoint space from dominant IV antibody franchises. Differentiation hinges on demonstrating clear efficacy in specific genetic subsets and the practical benefits of oral administration.